On May 6, 2024, T2 Biosystems, a company specializing in the rapid detection of sepsis-causing pathogens, announced the conversion of an additional $15 million of its term loan into equity. This transaction was conducted with entities affiliated with CRG Servicing LLC and follows a previous conversion of debt to equity that took place on April 12, 2024. The company has successfully reduced its total debt and quarterly interest payments by approximately 80% over the past year, significantly strengthening its balance sheet. John Sperzel, the Chairman and CEO of T2 Biosystems, highlighted the improvement in the company's financial position, which is expected to provide greater flexibility to advance its commercial and development priorities. T2 Biosystems is known for its innovative products like the T2Dx Instrument and various panels for pathogen detection, and it continues to develop new products such as the U.S. T2Resistance Panel and the T2Lyme Panel. The company's forward-looking statements indicate a focus on expanding product usage and achieving anticipated revenues, despite acknowledging the risks and uncertainties inherent in the market.

On May 6, 2024, T2 Biosystems, a company specializing in the rapid detection of sepsis-causing pathogens, announced the conversion of an additional $15 million of its term loan into equity. This transaction was conducted with entities affiliated with CRG Servicing LLC and follows a previous conversion of debt to equity that took place on April 12, 2024. The company has successfully reduced its total debt and quarterly interest payments by approximately 80% over the past year, significantly strengthening its balance sheet. John Sperzel, the Chairman and CEO of T2 Biosystems, highlighted the improvement in the company's financial position, which is expected to provide greater flexibility to advance its commercial and development priorities. T2 Biosystems is known for its innovative products like the T2Dx Instrument and various panels for pathogen detection, and it continues to develop new products such as the U.S. T2Resistance Panel and the T2Lyme Panel. The company's forward-looking statements indicate a focus on expanding product usage and achieving anticipated revenues, despite acknowledging the risks and uncertainties inherent in the market.